Recon Onkos Surgical® Announces Initiation of 522 Post-Market Surveillance Study of the ELEOS™ Limb Salvage System with NanoCept® Antibacterial Implant Technology byTim AllenFebruary 12, 2026
Recon Top Stories Onkos Surgical® Opens New Innovation Center for NanoCept® Antibacterial Technology byJosh SandbergDecember 10, 2025
Extremities Regulatory Onkos Surgical® Receives FDA 510(k) Clearance for ELEOS™ Proximal Tibia with NanoCept® Antibacterial Technology byJosh SandbergOctober 21, 2025
Recon Onkos Surgical® Successfully Completes Groundbreaking, First-in-Human Cases Using NanoCept™ Antibacterial Technology byTim AllenJanuary 9, 2025
Biologics Regulatory MCRA Supports Onkos Surgical with First FDA De Novo Approval for Antibacterial Coating for Implants byJosh SandbergJune 20, 2024
Recon Regulatory Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants byJosh SandbergApril 8, 2024
Top Stories Onkos Surgical Announces Expanded Capability in Pediatric Musculoskeletal Oncology and Unveils New Manufacturing and Innovation Center byJosh SandbergJuly 20, 2023
Recon Regulatory Top Stories Onkos Surgical Receives FDA 510(k) Clearance for 3D Printed, Patient-Specific Pelvic Reconstruction System byJosh SandbergJuly 14, 2022
Extremities Financial Top Stories Onkos Surgical Announces Definitive Agreement to Acquire the JTS Extendible Prosthesis byJosh SandbergJune 14, 2022
Extremities Regulatory Top Stories Onkos Surgical Announces FDA 510(k) Clearance of its BioGrip® Modular Porous Collars, a First-of-Its-Kind Solution to Help Address Implant Loosening in Orthopaedic Oncology and Complex Revision Surgery byJosh SandbergJune 22, 2021
